To examine whether high coronary risk patients in Australia, where
use of lipid-lowering drugs (LLD) is very high by international standards, are
A retrospective review of the persistence of bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian
rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD
(cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage.